Selinexor CAS# 1393477-72-9 塞利尼索
Selinexor, also known as KPT-330, is an orally bioavailable, potent and selective XPO1/CRM1 Inhibitor. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Selinexor potentiates the antitumor activity of gemcitabine in human pancreatic cancer through inhibition of tumor growth, depletion of the antiapoptotic proteins, and induction of apoptosis. Selinexor has strong activity against primary AML cells while sparing normal stem and progenitor cells.
📌 参考资料/链接：
Reference: Muthusamy, Anantha Rajmohan; Kanniah, Sundara Lakshmi; Ravi, Akash; Das, Tonmoy Chitta; Chemate, Rajendra Popat; Singh, Anil Kumar; Wagh, Yogesh Dhananjay. Novel crystalline forms of selinexor and process for their preparation. Assignee Watson Laboratories Inc., USA. WO 2018129227. (2018).
Reference: Muthusamy, Anantha Rajmohan; Kanniah, Sundara Lakshmi; Ravi, Akash; Das, Tonmoy Chitta; Chemate, Rajendra Popat; Singh, Anil Kumar; Wagh, Yogesh Dhananjay. Novel crystalline forms of selinexor and process for their preparation. Assignee Watson Laboratories Inc., USA. WO 2018129227. (2018).
📄 详细内容
CAS No. 1393477-72-9 塞利尼索Selinexor synthetic routes
Muthusamy, Anantha Rajmohan; Kanniah, Sundara Lakshmi; Ravi, Akash; Das, Tonmoy Chitta; Chemate, Rajendra Popat; Singh, Anil Kumar; Wagh, Yogesh Dhananjay. Novel crystalline forms of selinexor and process for their preparation. Assignee Watson Laboratories Inc., USA. WO 2018129227. (2018).
产品链接: CAS No. 1393477-72-9 ››
Muthusamy, Anantha Rajmohan; Kanniah, Sundara Lakshmi; Ravi, Akash; Das, Tonmoy Chitta; Chemate, Rajendra Popat; Singh, Anil Kumar; Wagh, Yogesh Dhananjay. Novel crystalline forms of selinexor and process for their preparation. Assignee Watson Laboratories Inc., USA. WO 2018129227. (2018).
产品链接: CAS No. 1393477-72-9 ››